Ilixadencel

As per DelveInsight's estimates, among the 7MM, the US captured the highest market of intra-tumoral cancer therapies of nearly USD 74 million in 2024, which is expected to increase due to the launch of emerging therapies such as CAN-2409, RP1 (vusolimogene oderparepvec), SP-002 (ASN-002), Bizaxofusp (MDNA55), and others. LAS VEGAS, May 19, 2025 /PRNewswire/ -- DelveInsight's Intra-tumoral Cancer Therapies Market report includes a comprehensive understanding of current treatment practices, emerging intra-tumoral cancer therapies, market share of individual therapies, and current and forecasted intra-tumoral cancer therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Intra-tumoral Cancer Therapies Market Report Currently, only three Intra-tumoral Cancer Therapies are approved; namely, IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen), approved in the US and Europe in 2015, DELYTACT (teserpaturev/G47Δ; Daiichi Sankyo) approved in Japan in 2021, and HENSIFY in Europe in 2019. As per DelveInsight's analysis, the total market size of intra-tumoral cancer therapies in the 7MM was USD 109 million in 2024 and is projected to grow during the forecast period (2025-2034). In 2024, the total cases of selected indication (based on current landscape and pipeline activity) were 8.9 million in the 7MM, which is anticipated to increase by 2034. Leading intra-tumoral cancer therapies companies, such as Janssen, Stamford Pharmaceuticals, Ascend Biopharmaceuticals, Replimune, Highlight Therapeutics, Cytovation ASA, Intensity Therapeutics, Ascendis Pharma, Treovir, Matica Biotechnology, QBiotics, NanOlogy, Lokon Pharma AB, EpicentRx, Medicenna Therapeutics, Philogen S.p.A., Candel Therapeutics, Lytix Biopharma, Verrica Pharmaceuticals, CEI-SCI, and others, and others, are developing novel intra-tumoral cancer therapies that are expected to enter the intra-tumoral cancer therapies market in the coming years. Some of the key intra-tumoral cancer therapies in the pipeline include INT230-6, Vusolimogene oderparepvec (RP1), Nidlegy (Daromun), G207, Ilixadencel (INTUVAX), Tigilanol tiglate, SP-002 (ASN-002), BO-112, Bizaxofusp (MDNA55), and others. In March 2025, NANOBIOTIX announced topline data from the completed dose-escalation portion of a Phase I study, conducted under the sponsorship of The University of Texas MD Anderson Cancer Center, evaluating JNJ-1900 (NBTXR3) activated by radiation therapy as a second-line or later (2L+) treatment for patients with locally advanced NSCLC eligible for re-irradiation. In March 2025, NANOBIOTIX announced an amendment to its global licensing agreement with Janssen Pharmaceutica NV. The amendment removes NANOBIOTIX's funding obligation for NANORAY- 312 and releases Johnson & Johnson from select future potential milestone payments while safeguarding NANOBIOTIX's path to sustainable cash flow through significant potential milestone payments. In March 2025, Candel Therapeutics and IDEA Pharma announced a strategic commercial partnership. Under this agreement, IDEA will provide strategic commercial input throughout the development and commercialization process for Candel's lead asset, CAN-2409. In January 2025, Lokon Pharma AB announced that the Food and Drug Administration (FDA) had granted Fast Track Designation (FTD) for the company's product candidate LOAd703 for the treatment of pancreatic cancer. In January 2025, Intensity Therapeutics announced that the Data Monitoring Committee (DMC) recommended the continuation of its Phase III sarcoma trial (INT230-6, INVINCIBLE-3) without modification based on data reviewed from July 2024 to December 2024. Some factors, such as the precedence of failure of emerging therapies, insufficient knowledge about Intra-tumoral Cancer Therapies , and several other drawbacks, might hinder the Intra-tumoral Cancer Therapies market growth. Discover which therapies are expected to grab the intra-tumoral cancer therapies market share @ Intra-tumoral Cancer Therapies Market Report Intra-tumoral Cancer Therapies Market Dynamics The intra-tumoral cancer therapies market dynamics are expected to change in the coming years. Various classes of intra-tumoral immunotherapies, including radioenhancer nanoparticles, recombinant fusion proteins, oncolytic therapy, gene therapy, synthetic dsRNA complexes, and others, are currently in preclinical and clinical development. These therapies increase drug concentration and availability within the tumor microenvironment while limiting systemic exposure and reducing the likelihood of immune-related side effects in other parts of the body. Intra-tumoral therapeutic strategies offer a powerful approach to in situ vaccine development, utilizing immune-stimulating agents to trigger local and systemic anti-tumor immune responses. Additionally, the ability of intra-tumoral immunotherapy combinations to elicit both T-cell and B-cell antitumor responses presents a potential strategy to overcome immune escape mechanisms, such as the loss of HLA-I expression on tumor cells, which are often associated with immune checkpoint therapy monoclonal antibody monotherapies. Furthermore, potential therapies are being investigated, and it is safe to predict that the treatment space will significantly impact the intra-tumoral cancer therapies market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the intra-tumoral cancer therapies market in the 7MM. However, several factors may impede the growth of the intra-tumoral cancer therapies market. The lack of standardized guidelines for intra-tumoral immunotherapy delivery results in variations in lesion selection, injection frequency, and needle technique, which directly affect treatment outcomes and safety. Patients are required to visit clinics for each dosing session, and the administration necessitates both trained radiologists and logistics support alongside skilled physicians. While research into intra-tumoral therapies has grown in recent years, several therapies, such as tilsotolimod/Ipilimumab, sotigalimab (APX005M), and vidutolimod (CMP-001), have failed clinical trials, impacting the market. Additionally, tumors with high intra-tumoral heterogeneity may lead to poorer clinical outcomes for patients. Intra-tumoral Cancer Therapies Therapeutics Market Although significant progress has been made in cancer treatment through methods like surgery, chemotherapy, radiation, immunotherapy, and targeted therapies, many of these treatments still face limitations such as systemic toxicity, inadequate tumor penetration, and poor targeting. These issues contribute to high mortality rates, underscoring the need for more precise and localized treatment options. Recently, cancer treatment strategies have increasingly focused on alternative delivery methods, including intra-tumoral administration. This approach is being actively researched, with several therapeutic candidates—such as immune receptor agonists, viral therapies, fusion proteins, monoclonal antibodies, and gene therapies—currently undergoing preclinical and clinical trials. Intra-tumoral immunotherapy, which involves directly delivering agents into or near the tumor site, is emerging as a promising approach. This strategy aims to boost localized immune responses while reducing systemic side effects. The first oncolytic virus, IMLYGIC (T-Vec; Amgen), was approved by the US FDA for treating unresectable melanoma lesions after surgery, following a Phase III trial. The European Commission approved the treatment of advanced melanoma in 2015. In 2019, Nanobiotix's HENSIFY (NBTXR3), a hafnium oxide nanoparticle therapy combined with radiation, received European approval for soft tissue sarcoma, with plans for data releases through 2025-2026 across multiple cancers. For STS the drug is approved in Europe but not yet launched. In Japan, DELYTACT (G47∆; Daiichi Sankyo) was granted conditional approval for malignant glioma, marking the first oncolytic virus for brain cancer, and is still under evaluation for its clinical benefits. IMLYGIC from Amgen is the first and only FDA-approved viral therapy that is injected directly into melanoma tumors. Despite the initial hype for this exciting intra-tumoral mode of cancer gene therapy, IMLYGIC's debut did not translate into much commercial success in the melanoma market. Limitations of the intra-tumoral administration, no statistically significant benefit in overall survival (OS), and the intense competition from immune checkpoint inhibitors (ICIs) due to their efficacy and manageable side effects are some of the main factors for ithe nsignificant revenues of this novel therapy. Learn more about the FDA-approved intra-tumoral cancer therapies @ Intra-tumoral Cancer Therapies Treatment Key Emerging Intra-tumoral Cancer Therapies and Companies The emerging pipeline of intra-tumoral cancer therapies is robust, including drugs from key players such as Candel Therapeutics (CAN-2409), Lytix Biopharma/Verrica Pharmaceuticals (LTX-315 [VP-315]), CEI-SCI (MULTIKINE), Philogen (Daromun [NIDLEGY; a combo of L19IL2 + L19TNF]), Replimune (RP2 and RP1 [vusolimogene oderparepvec]), Highlight Therapeutics (BO-112), Cytovation ASA (CY-101), Intensity Therapeutics (INT230-6), Ascendis Pharma (TransCon IL-2 β⁄γ), Treovir/Matica Biotechnology (G207), QBiotics (Tigilanol tiglate), NanOlogy (NanoPac), EpicentRx (AdAPT-001), Medicenna Therapeutics (Bizaxofusp [MDNA55]), and others. RP1 (vusolimogene oderparepvec), Replimune's lead product candidate, is based on a proprietary strain of Herpes Simplex Virus (HSV) engineered with a fusogenic protein (GALV-GP R-) and GM-CSF to enhance tumor killing potency, immunogenicity, and activation of a systemic antitumor immune response. In November 2024, Replimune announced that the FDA granted Breakthrough Therapy Designation (BTD) to RP1 in combination with nivolumab for the treatment of advanced melanoma in adult patients who have previously received an anti-PD1 regimen. Nidlegy is a biopharmaceutical product, proprietary to Philogen, designed for the treatment of skin cancer. It consists of two active ingredients, L19IL2 and L19TNF, which are manufactured independently and which are mixed prior to intralesional administration. In July 2024, Philogen and Sun Pharmaceutical announced that the European Medicines Agency (EMA) validated the submission of the Marketing Authorization Application (MAA) for Nidlegy. CAN-2409 (Candel Therapeutics) is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the HSV thymidine kinase (HSV-tk) gene to a patient's specific tumor and induce an individualized, systemic immune response against the tumor. In March 2025, according to the company's corporate highlights, the preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer are underway, with submission expected in Q4 2026. The anticipated launch of these emerging therapies are poised to transform the intra-tumoral cancer therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the intra-tumoral cancer therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about intra-tumoral cancer therapies clinical trials, visit @ Intra-tumoral Cancer Therapies Intra-tumoral Cancer Therapies Overview Cancer is a highly diverse disease, with its signs, symptoms, and treatments varying across different types, making it crucial to create targeted therapies for individual patients. Current treatment options for cancer include immunotherapy, radiotherapy, chemotherapy, targeted drug therapies, and more. While these approaches have improved OS and patient outcomes, they still have limitations and are not effective for everyone. Researchers are therefore working to develop new treatments that can overcome these challenges, with intra-tumoral cancer therapies emerging as a promising strategy. Intra-tumoral immunotherapy represents an innovative approach, where sophisticated antibodies are directly injected into tumors instead of being administered intravenously. This method focuses on delivering immunostimulatory agents straight into primary or metastatic tumor sites to initiate or enhance an antitumor immune response. Normally, the immune system detects and eliminates early tumors, but in immunosuppressive tumor environments, malignant cells can proliferate undetected. Regulatory T cells (Tregs), drawn to the tumor by chemokines, suppress Antigen-Presenting Cells (APCs) that would otherwise trigger an immune attack on tumor antigens. Moreover, tumor cells often release anti-inflammatory and regulatory cytokines like TGF-β and IL-10, which promote tumor growth and inhibit dendritic cell (DC) activation. To counteract this immunosuppressive environment, immunostimulants can be introduced. These agents work by attracting immune cells to the tumor or by activating the immune system to recognize and destroy cancer cells. Immunostimulants activate immune cells in the presence of tumor antigens, allowing them to travel to lymph nodes, where they stimulate tumor antigen-specific T cells through cross-presentation. These activated T cells can then return to the tumor or spread to distant tumors, leading to the targeted destruction of cancer cells. Intra-tumoral Cancer Therapies Epidemiology Segmentation In 2024, the total indication-wise treated cases of Intra-tumoral Cancer Therapies were 3.3 million in the 7MM, which is anticipated to increase by 2034. The intra-tumoral cancer therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Cases of Selected Indications Indication-wise Target Patient Pool of Intra-tumoral Cancer Therapies Indication-wise Treated Cases of Intra-tumoral Cancer Therapies Scope of the Intra-tumoral Cancer Therapies Market Report Intra-tumoral Cancer Therapies Therapeutic Assessment: Intra-tumoral current marketed and emerging therapies Intra-tumoral Cancer Therapies Market Dynamics: Conjoint Analysis of Emerging Intra-tumoral Cancer Therapies Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Intra-tumoral Cancer Therapies Market Access and Reimbursement Discover more about intra-tumoral cancer therapies in development @ Intra-tumoral Cancer Therapies Clinical Trials Table of Contents Related Reports Oncolytic Virus Market Oncolytic Virus Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of oncolytic virus, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key oncolytic virus companies, including Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, among others. Oncolytic Virus Competitive Landscape Oncolytic Virus Competitive Landscape – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key oncolytic virus companies, including Genelux Corporation, Candel Therapeutics, CG Oncology, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech, Replimune, Viralytics, Oncolys Biopharma, Istari Oncology, Immvira Pharma, Seneca Therapeutics, Treovir, LLC, Targovax, Lokon Pharma, ORCA Therapeutics, Beijing SyngenTech, ViruCure, Tasly Pharmaceuticals, Turnstone Biologics, BioInvent, Transgene, Elicera Therapeutics, Orgenesis, Virttu Biologics, Imugene, Astellas Pharma, Wuhan Binhui Biotechnology Co., Ltd., Mustang Bio, Virogin Biotech, Vaxiion Therapeutics, ImmVirX, Memgen, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, VCN Biosciences, Candel Therapeutics, Sorrento Therapeutics, Imugene Limited, Calidi Biotherapeutics, Replimune, TILT Biotherapeutics, Guangzhou Virotech Pharmaceutical, DNAtrix, Oncorus, BioEclipse Therapeutics, among others. Non-Small Cell Lung Cancer Market Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key NSCLC companies including AstraZeneca, Boehringer Ingelheim, Pfizer, Takeda, Johnson & Johnson Innovative Medicine, Eli Lilly and Company, Merck, Bristol-Myers Squibb, Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma, Moderna Therapeutics, Pfizer, GSK, Gilead Sciences, BieGene, Nuvalent , among others. Prostate Cancer Market Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including Janssen Research and Development, Sanofi, AstraZeneca, Merck, Pfizer, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen , among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

近日，莫菲特癌症中心的研究人员成功研发出一种新型癌症疫苗，有望用于治疗特定类型的乳腺癌，尤其是人类表皮生长因子受体 2 阳性（HER2 阳性）、雌激素受体阴性（ER 阴性）的乳腺癌。该创新疗法在最近的一项试点研究中取得了令人鼓舞的成果，相关研究成果已发表于《npj Breast Cancer》杂志中。 研究表明，针对 HER2 蛋白的树突状细胞疫苗不仅能够增强免疫系统对肿瘤的攻击能力，提升化疗效果，而且将疫苗直接注射到肿瘤中，还可以激活肿瘤环境中的免疫细胞，这一发现或有助于完善未来针对乳腺癌及其他癌症的免疫治疗策略。 专家指出，通过刺激免疫系统，该疫苗有望为患者带来更为有效且持久的治疗反应，为强化乳腺癌治疗效果、改善患者预后开辟全新途径！ ▲截图源自“npj” 一、莫菲特癌症中心重大突破：HER2 靶向树突状细胞疫苗改写乳腺癌治疗格局，病理完全缓解率跃升至64.5% 既往研究表明，在乳腺癌从初始状态发展为完全侵袭性肿瘤的过程中，关键肿瘤相关抗原（如HER2）的免疫识别会下降。这一现象可能源于免疫编辑以及肿瘤介导的免疫抑制增强，而这又进一步推动了恶性肿瘤的扩散。不过，部分乳腺肿瘤会引发大量T细胞流入。多项研究显示，相较于免疫学上的“冷”肿瘤，这类肿瘤患者的预后更佳。 而树突状细胞（DC）作为强大的抗原呈递细胞，在启动和调节免疫反应中发挥着关键作用，能够激活T细胞以识别并摧毁癌细胞。其中，1型树突状细胞（DC1）是一种特殊亚型，其在抗原交叉呈递方面表现卓越，可促进针对靶向抗原的1型适应性细胞免疫反应。研究发现，通过将采血获得的自体树突状细胞与具有免疫原性的HER2肽在体外共同刺激，能够制备出HER2靶向DC1疫苗。这类HER2DC1疫苗能够逆转肿瘤介导的免疫抑制，重新建立对HER2表位的识别，并且在注射到引流腋窝淋巴结中时，可促使早期乳腺癌消退。 ▼下图中三个T细胞（蓝色）正在攻击和分解癌细胞 ▲图源“SciTechDaily”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 莫菲特癌症中心开展的此项研究，共纳入30例2期和3期HER2阳性、ER阴性乳腺癌患者，将其分为三组，即A组6例、B组6例、C组18例。这些患者在手术前接受化疗以缩小肿瘤。研究人员在化疗前为患者注射HER2靶向树突状细胞疫苗，旨在明确该疫苗对免疫反应及治疗结果的影响。 结果令人振奋：接种疫苗的患者免疫系统活性显著提升，部分病例中肿瘤完全消退。截至2023年11月10日，中位随访期为32.8个月。所有组别中可评估患者的 总体病理完全缓解率（pCR）率为64.5% （20/30，95%CI：45.4–80.8）， 无病生存率和总生存率达93.3% 。其中， A、B、C组的病理完全缓解率（pCR）分别为42.8%、66.6%和72.7% （详见下表）。 综上，HER2阳性乳腺癌属于侵袭性亚型，过去常用曲妥珠单抗等HER2靶向疗法进行治疗，然而许多患者会产生耐药性。这项研究表明，将树突状细胞疫苗与化疗相结合，能够调动免疫系统对抗疾病，为治疗带来额外优势。 二、自体DC疫苗联合阿维单抗，MSS转移性结肠癌中位总生存期翻倍增长 免疫检查点阻断（ICB）已被证实，对错配修复缺陷/微卫星不稳定的高转移性结直肠癌（mCRC）具有临床疗效。然而，对于错配修复功能良好/微卫星稳定（MSS）的结肠癌，ICB的疗效却十分有限，其最佳总体反应（BOR）低于5%，中位无进展生存期（PFS）仅为2.2个月，中位总生存期（OS）仅为5个月，且6个月时的PFS低于20%。在这种情况下，癌症疫苗有望成为ICB的补充治疗手段。这类疫苗旨在刺激肿瘤抗原特异性细胞毒性T淋巴细胞，使其能够以抗原特异性的方式识别并可能清除癌细胞，进而将免疫学上的“冷”肿瘤转变为“热”肿瘤。 一项名为“ 自体树突状细胞（DC）疫苗+Avelumab（阿维单抗）治疗转移性结直肠癌的I-II期GEMCAD1602临床研究 ”，纳入了19例错配修复功能良好（MSS）的转移性结直肠癌患者。这些患者均至少接受过2种化疗方案的治疗，且都使用过伊立替康、奥沙利铂和氟嘧啶类药物，其既往治疗次数的中位数为3次（范围：2~5次）。 研究结果显示： 4例患者病情稳定（占比22%） ， 中位无进展生存期（PFS）为3.1个月 （范围：2.1~5.3个月）， 总生存期（OS）为12.2个月 （范围：3.2~23.2个月），与单独接受免疫检查点阻断（ICB）相比（仅5个月），此次 联合治疗方案下的中位OS提高幅度超过一倍。 ▲图源“Cancer Immunol Immunother”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 综上所述，Avelumab联合ADC疫苗的治疗方案安全且耐受性良好，但临床活性适中。 三、自体DC疫苗重锤惰性非霍奇金淋巴瘤，3例患者成功实现完全缓解 惰性非霍奇金淋巴瘤（NHL）对化疗敏感，但无法通过化疗治愈，其生长缓慢且以持续复发为特点，因此，探寻新的治疗手段迫在眉睫。 全球知名血液学期刊《Blood》曾报道一项“应用自体肿瘤树突状细胞（DC）疫苗，治疗惰性B细胞淋巴瘤的初步研究”。该研究共纳入18例患有可测量的惰性非霍奇金淋巴瘤（NHL）且至少接受过一次放化疗后复发的患者，其中包括12例滤泡性淋巴瘤（FL）患者、6例淋巴浆细胞样淋巴瘤患者，这些患者先前接受治疗方案的中位数为2次（范围1-5次）。入组患者接种了自体肿瘤细胞的树突状细胞（DC），中位随访时间为50.5个月（范围7-63个月）。 结果显示：该疫苗接种 耐受性良好，未出现自身免疫反应，且取得了显著的客观临床反应 ，与显著的免疫调节相关。在18名患者中， 有6例患者（33.3%）出现客观缓解（ORR），其中3例患者奇迹般达到完全缓解（CR）、3例患者达到部分缓解（PR），另外8例患者病情稳定（SD）。 其中有两位患者的情况值得特别关注： 第一位患者（患者12）在CVP（环磷酰胺、长春新碱和泼尼松）方案后复发时，接种了DC疫苗，彼时其外周血（PB）和骨髓（BM）中有肿瘤特异性IgH PCR信号，且在CVP治疗后及参与本研究之前达到了完全缓解（CR），并持续了36个月。最后一次注射DC疫苗6个月后，该患者 纵隔和腋窝淋巴结的CT扫描显示达到完全缓解 ，并且 外周血（PB）和骨髓（BM）中的肿瘤特异性PCR信号消失 （详见下图）。振奋人心的是，目前， 该患者在未接受额外抗癌治疗的情况下，已维持49个月的完全缓解（CR）状态 。 ▼12号患者的胸部CT扫描图像 ▲图源“Blood”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 注： ①左图：DC疫苗治疗前的CT图像：该患者存在多个小的肿大的纵隔和左腋窝淋巴结（左，箭头）； ②右图：接种DC疫苗6个月后的CT图像：病灶恢复正常。 第二位患者（患者5）既往接受过利妥昔单抗治疗。在最后一次注射DC疫苗6个月后，其 腹膜后淋巴结CT扫描显示达到部分缓解（PR） ，同时 骨髓中肿瘤特异性IgHPCR信号呈阴性 （详见下图）。 该患者的部分缓解（PR）持续了12个月 ，之后记录到与腹膜后淋巴结进展相关的BMPCR信号。 此后，患者接受HDS化疗方案，在42个月的随访中实现持续完全缓解（CR） 。 ▼5号患者的胸部CT扫描图像 ▲图源“Blood”，版权归原作者所有，如无意中侵犯了知识产权，请联系我们删除 注： ①左图：DC疫苗治疗前CT图像显示，腹膜后淋巴结肿大； ②右图：接种DC疫苗疫苗4个月后，CT图像显示：腹膜后淋巴结缩小。 总之，这些结果表明，接种载有肿瘤的DC疫苗可能诱导T细胞和B细胞反应，为患有可测量疾病的惰性NHL患者带来临床益处。 四、聚焦前沿：树突细胞（DC）疫苗的研发与应用现状 相信看完上述介绍，癌症患者们对DC疫苗已有了初步认识。除了前文提到的几款取得突破性进展的DC疫苗外，还有众多处于临床试验阶段的DC疫苗，包括但不限于： 1、 DCVAC/LuCa疫苗：针对非小细胞肺癌 DCVAC/LuCa是美国研发的一款用于非小细胞肺癌患者的树突状细胞疫苗。在2019年美国临床肿瘤学会（ASCO）大会上，一项冲击晚期肺癌一线治疗方案的研究结果公布：DCVAC/LuCa疫苗联合化疗组的客观缓解率（ORRT）达45%，中位总生存期（OS）为15.5个月，中位无进展生存期（PFS）为6.74个月，死亡风险降低46%。 2、 Tedopi疫苗：针对非小细胞肺癌 2020年4月1日，新型抗癌疫苗Tedopi在非小细胞肺癌的Ⅲ期临床试验中取得阳性结果。入组的所有患者在免疫检查点抑制剂（PD-1）耐药或治疗失败后，接受二线或三线Tedopi疫苗治疗，一年的总生存（OS）率达到46%，远超预设的25%。 3、 DCVAC/OvCa疫苗：针对卵巢癌 SOV02二期临床试验显示：对于复发、铂敏感的上皮卵巢癌患者，在标准卡铂和吉西他滨方案中加入基于树突状细胞的免疫疗法DCVAC/OvCa，可使晚期复发的卵巢癌患者总生存期（OS）延长一年多。而且，DCVAC/OvCa将卵巢癌二线治疗的死亡风险降低了62％，总生存期（OS）显著增加13.4个月，中位数无进展生存率（mPFS）增加了1.8个月。 此外，还有针对肾癌的Ilixadencel疫苗、针对胶质母细胞瘤的AV-GBM-1疫苗等。不过，目前大多数DC疫苗仍处于临床试验阶段，患者若想接受治疗，只能通过申请临床试验入组。比如DCvax-L疫苗已进入三期临床试验，有望获批上市，我们期待看到更多详实有效的数据。此外，在一些国家，树突细胞疫苗已正式投入临床应用。 五、小编寄语 癌症作为一种高度复杂且突变频繁的疾病，仅依靠单一治疗手段，很难达到理想的治疗效果。目前，较为理想的治疗策略是在权威医院进行手术、放化疗等传统治疗的基础上，综合考虑患者的病情严重程度、个体体质差异、突变靶点特征以及经济状况等多方面因素，合理辅助靶向药物、免疫细胞治疗（如CAR-T、TCR-T、TIL细胞疗法、DC疫苗等）、质子治疗、电场疗法等新型治疗手段。通过这种多管齐下的治疗方式，能够巩固传统治疗的效果，降低肿瘤复发风险，提高患者的生存质量，并有效延长生存期。 上文所提及的树突状细胞（DC），是机体内唯一能够激活初始T细胞的抗原提呈细胞，在机体的免疫反应中扮演着举足轻重的角色。DC疫苗正是巧妙利用了树突状细胞这一独特的免疫特性来治疗癌症。现阶段，DC疫苗大多还处于早期临床试验阶段，我们满怀期待，希望能获取更多关于其有效性的数据。值得一提的是，在一些国家，树突细胞疫苗已正式投入临床应用。对于部分早期肿瘤患者而言，在手术后可考虑采用树突细胞联合放化疗的辅助治疗方案，这有助于清除残留的癌细胞，形成免疫记忆，从而有效预防癌症的复发和转移。 六、参考资料 [1]https://www.dailymail.co.uk/health/article-12917693/Injection-stem-cells-mens-sex-lives-lift.html [2]Ligia J,et al.Morley (2009) Anti-aging medicine: pitfalls and hopes,The Aging Male,12:1,13-20,DOI:10.1080/13685530902814434 https://www-tandfonline-com.libproxy1.nus.edu.sg/doi/full/10.1080/13685530902814434 [3]Godic A.The role of stem cells in anti-aging medicine[J]. Clinics in Dermatology, 2019, 37(4): 320-325. https://www-sciencedirect-com.libproxy1.nus.edu.sg/science/article/abs/pii/S0738081X19300781 本文为全球肿瘤医生网原创，未经授权禁止转载。